NGNE
Neurogene Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Neurogene Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Neurogene Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Neurogene Inc.'s 6 closest co-movers, none share that code.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
No other changes.
No other changes.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
Inputs8Q avg ±6.2%·×2.36·rich
straddle ±17.7%
spot 27.58exp Nov 20ATM strike 30ATM straddle 5.75IV 113%
−2.05%
vs ±13.1% implied · ×0.16
shaded = implied · ▲▼ = realized
Annual filing, covered
10-K parsed · Mar 24 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 24 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Neurogene Inc.
27.16
−0.42 · −1.51%
| Manager | Value | % base | |
|---|---|---|---|
| Samsara BioCapital | $54.0M | 9.84% | 0.00% |
| Casdin Capital | $48.6M | 8.86% | +8.80% |
| Redmile | $44.4M | 8.09% | −3.25% |
| RTW | $42.8M | 7.81% | 0.00% |
| EcoR1 Capital | $40.0M | 7.29% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Samsara BioCapital | $54.0M | 9.84% | 0.00% |
| Casdin Capital | $48.6M | 8.86% | +8.80% |
| Redmile | $44.4M | 8.09% | −3.25% |
| RTW | $42.8M | 7.81% | 0.00% |
| EcoR1 Capital | $40.0M | 7.29% | 0.00% |
Bull1
Bear2